RT Journal Article
SR Electronic
T1 Management of Challenging Radioiodine Treatment Protocols: A Case Series and Review of the Literature
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 180
OP 185
DO 10.2967/jnmt.120.255307
VO 49
IS 2
A1 Joseph Waller
A1 Courtney A. Lawhn-Heath
A1 Cathleen Edmonds
A1 Chloee Wendorf
A1 Brandon Holmes
A1 Michael White
A1 Miguel Hernandez Pampaloni
A1 Chienying Liu
A1 Robert R. Flavell
YR 2021
UL http://tech.snmjournals.org/content/49/2/180.abstract
AB Radioactive iodine (RAI) therapy with 131I is the standard of care for treatment in many patients with differentiated thyroid cancer. Because 131I is typically administered as a pill, and much of its radioactivity is excreted via the urine, there can be challenges in patients who cannot swallow pills, absorb iodine via the gastrointestinal tract, or eliminate RAI via the urine (i.e., dialysis patients and patients with renal failure). In this article, we present 3 cases in which the standard 131I treatment protocol for thyroid cancer could not be used because of these challenges, and we discuss the strategies used to overcome them. Provider collaboration and treatment customization are critical in overcoming patient-specific challenges.